Literature DB >> 21785914

Revisiting the role of molecular targeted therapies in patients with brain metastases.

Dionysis Papadatos-Pastos1, Udai Banerji.   

Abstract

Brain metastases (BM) are treated with surgical resection when feasible. Unfortunately this occurs only in a small subset of patients. The optimal treatment for patients with intracranial metastases non amenable to surgical resection has not been identified. Radiotherapy improves symptom control and survival but long-term local control has been poor. Conventional chemotherapies have generally produced disappointing results possibly due to their limited ability to penetrate the blood brain barrier. Therefore, newer treatments are required for patients with unresectable BM. Targeted therapies such as bevacizumab, erlotinib, gefitinib, sunitinib and sorafenib, are all licensed and have demonstrated improved survival in patients with metastatic disease. In this review we will present current data on targeted therapies that have been approved for the treatment of malignant tumours and we discuss the evidence of their use in patients with BM.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21785914     DOI： 10.1007/s11060-011-0661-y

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  81 in total

Review 1.  The diagnosis and management of brain metastases.

Authors:  M J van den Bent
Journal:  Curr Opin Neurol       Date:  2001-12       Impact factor: 5.710

2.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).

Authors:  B C Pestalozzi; D Zahrieh; K N Price; S B Holmberg; J Lindtner; J Collins; D Crivellari; M F Fey; E Murray; O Pagani; E Simoncini; M Castiglione-Gertsch; R D Gelber; A S Coates; A Goldhirsch
Journal:  Ann Oncol       Date:  2006-04-07       Impact factor: 32.976

3.  Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival.

Authors:  Elyse E Lower; D Randolph Drosick; Robbin Blau; Lawrence Brennan; William Danneman; Douglas K Hawley
Journal:  Clin Breast Cancer       Date:  2003-06       Impact factor: 3.225

4.  Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

Authors:  Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

5.  Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.

Authors:  Shenglin Ma; Yaping Xu; Qinghua Deng; Xinmin Yu
Journal:  Lung Cancer       Date:  2008-12-16       Impact factor: 5.705

Review 6.  Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.

Authors:  Yoshinobu Namba; Takashi Kijima; Soichiro Yokota; Manabu Niinaka; Satolo Kawamura; Takeo Iwasaki; Yoshito Takeda; Hiromi Kimura; Tatsuya Okada; Toshihiko Yamaguchi; Masaru Nakagawa; Yoshimoto Okumura; Hajime Maeda; Masami Ito
Journal:  Clin Lung Cancer       Date:  2004-09       Impact factor: 4.785

7.  Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Authors:  Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

8.  Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.

Authors:  Mark A Socinski; Corey J Langer; Jane E Huang; Margaret M Kolb; Peter Compton; Lisa Wang; Wallace Akerley
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

9.  Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment.

Authors:  E Shmueli; N Wigler; M Inbar
Journal:  Eur J Cancer       Date:  2004-02       Impact factor: 9.162

Review 10.  The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.

Authors:  Steven N Kalkanis; Douglas Kondziolka; Laurie E Gaspar; Stuart H Burri; Anthony L Asher; Charles S Cobbs; Mario Ammirati; Paula D Robinson; David W Andrews; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Mark E Linskey
Journal:  J Neurooncol       Date:  2009-12-04       Impact factor: 4.130
View more
  5 in total

Review 1.  Brain metastases: an overview.

Authors:  F Bertolini; A Spallanzani; A Fontana; R Depenni; G Luppi
Journal:  CNS Oncol       Date:  2015

2.  Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.

Authors:  Mrinal M Gounder; Lakshmi Nayak; Solmaz Sahebjam; Alona Muzikansky; Armando J Sanchez; Serena Desideri; Xiaobu Ye; S Percy Ivy; L Burt Nabors; Michael Prados; Stuart Grossman; Lisa M DeAngelis; Patrick Y Wen
Journal:  J Clin Oncol       Date:  2015-08-17       Impact factor: 44.544

3.  The efficacy and limitations of stereotactic radiosurgery as a salvage treatment after failed whole brain radiotherapy for brain metastases.

Authors:  Shoji Yomo; Motohiro Hayashi
Journal:  J Neurooncol       Date:  2013-05-10       Impact factor: 4.130

Review 4.  Neurosurgical management of brain metastases.

Authors:  Sherise D Ferguson; Kathryn M Wagner; Sujit S Prabhu; Mary F McAleer; Ian E McCutcheon; Raymond Sawaya
Journal:  Clin Exp Metastasis       Date:  2017-09-30       Impact factor: 5.150

5.  Safety, efficacy and survival of patients with primary malignant brain tumours (PMBT) in phase I (Ph1) trials: the 12-year Royal Marsden experience.

Authors:  Niamh Coleman; Vasiliki Michalarea; Scheryll Alken; Karim Rihawi; Raquel Perez Lopez; Nina Tunariu; Ann Petruckevitch; L R Molife; Udai Banerji; Johann S De Bono; Liam Welsh; Frank Saran; Juanita Lopez
Journal:  J Neurooncol       Date:  2018-04-10       Impact factor: 4.130
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.